KLTO

Klotho Neurosciences, Inc. Common Stock
KLTO

0.3490 USD
+0.0180
5.44%
At close Nov 18, 4:00 PM EST
After hours
0.3003
-0.0487
13.95%
1 day
5.44%
5 days
8.05%
1 month
-53.92%
3 months
-60.79%
6 months
-60.79%
Year to date
-60.79%
1 year
-60.79%
5 years
-60.79%
10 years
-60.79%
 

About: Klotho Neurosciences Inc is in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders.

0
Funds holding %
of 6,704 funds
–
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

3.78% more ownership

Funds ownership: 0% [Q2] → 3.78% (+3.78%) [Q3]

36% less funds holding

Funds holding: 11 [Q2] → 7 (-4) [Q3]

64% less capital invested

Capital invested by funds: $1.46M [Q2] → $527K (-$937K) [Q3]

67% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 6

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for KLTO.

See Analyst Rankings

Financial journalist opinion

Neutral
MCAP MediaWire
3 weeks ago
Dr. Makoto Kuro-o, Pioneer of the Klotho Anti-Aging Gene, Joins Klotho Neurosciences, Inc. as Scientific Advisor
Discoverer of Klotho gene further strengths KLTO Scientific Advisory Board New York, NY, October 23, 2024 – PRISM MediaWire – Klotho Neurosciences, Inc. (NASDAQ: KLTO), a leading biotechnology company focused on developing cell and gene therapies for aging and age-related diseases, is proud to announce the appointment of Dr.
Dr. Makoto Kuro-o, Pioneer of the Klotho Anti-Aging Gene, Joins Klotho Neurosciences, Inc. as Scientific Advisor
Neutral
GlobeNewsWire
3 weeks ago
Dr. Makoto Kuro-o, Pioneer of the Klotho Anti-Aging Gene, Joins Klotho Neurosciences, Inc. as Scientific Advisor
NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a leading biotechnology company focused on developing cell and gene therapies for aging and age-related diseases, is proud to announce the appointment of Dr. Makoto Kuro-o to its Scientific Advisory Board. Dr. Kuro-o, a distinguished Japanese physician-scientist, is widely recognized as the pioneer behind the discovery of the Klotho gene, often referred to as the "anti-aging gene.
Dr. Makoto Kuro-o, Pioneer of the Klotho Anti-Aging Gene, Joins Klotho Neurosciences, Inc. as Scientific Advisor
Neutral
MCAP MediaWire
1 month ago
Co-Founder of Shire Pharmaceuticals Appointed as Chief Operating Officer of Klotho Neurosciences
KLTO strengthens team with industry veteran and is poised to accelerate the development of its therapeutic candidates New York, NY, October 15, 2024 – PRISM MediaWire – Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.
Co-Founder of Shire Pharmaceuticals Appointed as Chief Operating Officer of Klotho Neurosciences
Neutral
GlobeNewsWire
1 month ago
Co-Founder of Shire Pharmaceuticals Appointed as Chief Operating Officer of Klotho Neurosciences
NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biotechnology company pioneering cell and gene therapies for aging and age-related diseases, today announced the appointment of Peter Moriarty, Co-Founder of Shire Pharmaceuticals, as its Chief Operating Officer (COO). Dr. Joseph Sinkule, Chairman, CEO, and Founder of Klotho Neurosciences, welcomed Moriarty to the leadership team: “We are thrilled to have Peter join Klotho Neurosciences as COO.
Co-Founder of Shire Pharmaceuticals Appointed as Chief Operating Officer of Klotho Neurosciences
Neutral
MCAP MediaWire
1 month ago
Dr. Robert Langer, Co-Founder of Moderna, Joins Scientific Advisory Board of Klotho Neurosciences, Inc. (KLTO)
Renowned Biotech Leader to Contribute Expertise in Neuroscience and Therapeutics Development New York, NY, September 30, 2024 – PRISM MediaWire – Klotho Neurosciences, Inc. (NASDAQ: KLTO), a cutting-edge biotechnology company focused on developing innovative therapies for neurodegenerative diseases and promoting healthy longevity, is proud to announce that Dr.
Dr. Robert Langer, Co-Founder of Moderna, Joins Scientific Advisory Board of Klotho Neurosciences, Inc. (KLTO)
Neutral
GlobeNewsWire
1 month ago
Dr. Robert Langer, Co-Founder of Moderna, Joins Scientific Advisory Board of Klotho Neurosciences, Inc. (KLTO)
NEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a cutting-edge biotechnology company focused on developing innovative therapies for neurodegenerative diseases and promoting healthy longevity, is proud to announce that Dr. Robert Langer, co-founder of Moderna, has joined its Scientific Advisory Board.
Dr. Robert Langer, Co-Founder of Moderna, Joins Scientific Advisory Board of Klotho Neurosciences, Inc. (KLTO)
Neutral
GlobeNewsWire
1 month ago
Dr. Robert Langer, Co-Founder of Moderna, Joins Scientific Advisory Board of Klotho Neurosciences, Inc. (KLTO)
NEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a cutting-edge biotechnology company focused on developing innovative therapies for neurodegenerative diseases and promoting healthy longevity, is proud to announce that Dr. Robert Langer, co-founder of Moderna, has joined its Scientific Advisory Board.
Dr. Robert Langer, Co-Founder of Moderna, Joins Scientific Advisory Board of Klotho Neurosciences, Inc. (KLTO)
See News Rankings
Charts implemented using Lightweight Charts™